GV and Celgene-backed Armo BioSciences has filed to raise up to $86.3m in an offering that will fund clinical tests for its lead immuno-oncology candidate.

The Novo and Merck-backed pruritus therapy developer has filed to raise up to $97.8m, having already secured almost $110m in VC funding.

Biogen-backed Duchenne muscular dystrophy (DMD) treatment developer Solid Biosciences has filed to raise up to $100m.

LexinFintech, the instalment buying platform operator backed by Bertelsmann, JD.com and Taikang, had initially targeted $500m in the offering.

Broadband software provider Casa Systems, backed by Liberty Global Ventures, has gone public in a downgraded initial public offering.

University of Minnesota spinout Calyxt has entered the public markets in a flotation that resulted in the share price climbing from $8 to $11.25 on the first day of trading.

Video advertising software developer Mirriad aims to raise $35m in a London initial public offering that will score exits for Unilever, STV and Zee Entertainment.

University of Surrey in-video advertising spinout Mirriad is set to raise $35m in an initial public offering at a market cap of $84.4m.

Quanterix, a digital immunoassay developer spun out of Tufts University, has raised $64.1m in its initial public offering.

Quanterix, a digital immunoassay developer backed by BioMerieux and Stratec, has raised $64.1m in its initial public offering.